Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California 92093, USA.
J Nat Prod. 2010 Apr 23;73(4):709-11. doi: 10.1021/np9005184.
Fractionation of the extract of the marine cyanobacterium Lyngbya majuscula collected from Panama led to the isolation of malyngolide dimer (1). The planar structure of 1 was determined using 1D and 2D NMR spectroscopy and HRESI-TOFMS. The absolute configuration was established by chemical degradation followed by chiral GC-MS analyses and comparisons with an authentic sample of malyngolide seco-acid (4). Compound 1 showed moderate in vitro antimalarial activity against chloroquine-resistant Plasmodium falciparum (W2) (IC(50) = 19 microM) but roughly equivalent toxicity against H-460 human lung cell lines. Furthermore, because the closely related cyanobacterial natural product tanikolide dimer (5) was a potent SIRT2 inhibitor, compound 1 was evaluated in this assay but found to be essentially inactive.
从巴拿马采集的海洋蓝藻 Lyngbya majuscula 的提取物进行分段提取,得到了马缨丹内酯二聚体(1)。通过 1D 和 2D NMR 光谱和 HRESI-TOFMS 确定了 1 的平面结构。通过化学降解,然后进行手性 GC-MS 分析,并与马缨丹内酯 seco-acid(4)的真实样品进行比较,确定了其绝对构型。化合物 1 对氯喹耐药的恶性疟原虫(W2)(IC(50)= 19 μM)表现出中等的体外抗疟活性,但对 H-460 人肺细胞系的毒性大致相当。此外,由于密切相关的蓝藻天然产物 tanikolide 二聚体(5)是一种有效的 SIRT2 抑制剂,因此对化合物 1 进行了该测定,但发现其基本上无活性。